Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly's $8 Billion Oncology Bet Gets Its Chance to Succeed

By Cory Renauer – May 9, 2020 at 10:27AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Retevmo, the asset that inspired Eli Lilly's acquisition of Loxo Oncology, has earned approval to treat aggressive tumors.

In early 2019, Eli Lilly (LLY 2.59%) made an $8 billion bet on the future of cancer treatment with an $8 billion buyout offer for Loxo Oncology and its pipeline of targeted cancer therapies. On Friday, the jewel at the center of the acquisition, LOXO-292, earned approval from the FDA to hammer away at aggressive tumors driven by RET mutations. 

Highly targeted

Under the brand name Retevmo, Lilly's RET inhibitor is approved in the U.S. to treat very specific groups of patients with tumors originating in their lungs and thyroid glands. Retevmo's an easy-to-swallow capsule designed to stop mutated RET kinases from driving tumor growth, a condition that describes a low double-digit percentage of thyroid cancers. 

Smiling laboratory professional

Image source: Getty Images.

Aggressive RET mutant tumors are also found in around 2% of patients with non-small cell lung cancer (NSCLC). While NSCLC isn't the most frequently diagnosed malignancy, it claims more lives than any other. Retevmo could become the go-to treatment for enough patients to drive annual sales above $1 billion within a couple of years following its approval.

Accelerated approval

The FDA approved Retevmo based on signs of tumor shrinkage, not actual survival outcomes. An impressive 64% of NSCLC patients treated with Retevmo in the second-line setting responded to the new therapy. Among those that hadn't already been treated with standard chemotherapy, Retevmo shrank tumors 84% of the time.

The FDA could withdraw or curtail Retvmo's accelerated approval if the treatment fails to provide a survival benefit in two confirmatory trials that are enrolling patients at the moment. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$329.89 (2.59%) $8.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.